Stonegate Capital Partners has issued an updated research report on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage central nervous system (CNS) oncology company focused on developing therapies that cross the blood-brain barrier (BBB). The coverage emphasizes the company's progress with its lead drug candidate NEO212, a next-generation version of the standard chemotherapy temozolomide (TMZ), designed to address key limitations such as BBB penetration and MGMT-driven resistance, a common cause of treatment failure in glioblastoma (GBM).
According to the report, NeOnc's NEO212 has completed Phase 1 dose escalation in recurrent GBM, establishing a Recommended Phase 2 Dose of 610 mg with early signs of disease control. This positions the program to advance into Phase 2 efficacy evaluation, targeting a large patient population where standard TMZ therapy often fails. The company's platform also includes NEO100, an intranasal therapy that delivers drugs directly to the brain non-invasively. Phase 2 data for NEO100 showed radiographic responses and improved progression-free survival compared to historical salvage benchmarks in recurrent GBM.
Beyond its lead programs, NeOnc's platform approach combines intranasal and oral drug delivery technologies designed to improve CNS drug penetration, supporting additional opportunities across multiple brain tumor indications. The company recently completed a successful PIPE offering, adding gross proceeds of $16.0 million to its balance sheet, providing capital to advance its pipeline.
The full announcement, including downloadable images and bios, can be accessed here. Stonegate Capital Partners is a capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Its affiliate, Stonegate Capital Markets (member FINRA), offers investment banking services.
